Nanoparticle-Mediated targeted drug delivery for cancer therapy.

Nikolaus Gibran*
Department of Pharmaceutical Technology, University in Dortmund, Poststell, Germany

Received date: *January 21, 2023, Manuscript No. AJPTI-23-92296;* ***Editor assigned date:*** *January 26, 2023, Pre QC No. AJPTI-23-92296(PQ);* ***Reviewed date:*** *February 16, 2023, QC No. AJPTI-23-92296;* ***Revised date:*** *February 23, 2023, Manuscript No. AJPTI-23-92296(R);* ***Published date:*** *February 28, 2023.*

Accepted on 25th February, 2023

Description

Cancer is a debilitating and often deadly disease that affects millions of people worldwide. Traditional cancer treatments, such as chemotherapy and radiation, have many side effects and often result in damage to healthy cells. However, in recent years, there has been much research on developing new cancer therapies that are more targeted and have fewer side effects. One promising area of research is nanoparticle-mediated targeted drug delivery for cancer therapy.

Nanoparticles and drug delivery

Nanoparticles are tiny particles that are typically between 1 and 100 nanometers in size. They are able to penetrate cells and tissues more easily than larger particles and can be designed to carry drugs or other therapeutic agents. The use of nanoparticles for drug delivery has many advantages over traditional drug delivery methods. For example, nanoparticles can be designed to release drugs in a controlled manner, which can increase their effectiveness and reduce side effects.

Targeted drug delivery is a method of delivering drugs specifically to cancer cells while sparing healthy cells. This can be accomplished through the use of nanoparticles that are designed to recognize and bind to cancer cells. Once bound, the nanoparticles can release their cargo of drugs, which can then kill the cancer cells.

Targeted drug delivery using nanoparticles is the use of liposomes. Liposomes are spherical nanoparticles that are composed of a lipid bilayer. They can be designed to carry drugs and have a high affinity for cancer cells. Once the liposomes are taken up by the cancer cells, they release their drugs, which can kill the cancer cells. Liposomes have been shown to be effective in treating a variety of cancers, including breast cancer and lung cancer and nanoparticles is the use of dendrimers. Dendrimers are branched nanoparticles that can be designed to carry drugs and other therapeutic agents. They can also be functionalized with targeting molecules that recognize and bind to cancer cells. Once the dendrimers are taken up by the cancer cells, they release their cargo of drugs, which can kill the cancer cells. Dendrimers have been shown to be effective in treating a variety of cancers, including prostate cancer and pancreatic cancer.

There are several advantages to using nanoparticle-mediated targeted drug delivery for cancer therapy. One advantage is that it can reduce side effects. Because the drugs are targeted specifically to cancer cells, healthy cells are spared from the toxic effects of the drugs. This can reduce side effects such as nausea, hair loss, and fatigue. Another advantage is that it can increase the effectiveness of the drugs. By delivering drugs specifically to cancer cells, nanoparticle-mediated targeted drug delivery can increase the concentration of drugs at the site of the cancer. This can increase the effectiveness of the drugs and reduce the likelihood of cancer recurrence. Nanoparticle-mediated targeted drug delivery is a promising area of research for cancer therapy. By using nanoparticles to deliver drugs specifically to cancer cells, it is possible to reduce side effects and increase the effectiveness of the drugs. While there are still many challenges to be overcome, including optimizing the design of the nanoparticles and developing effective targeting strategies, the potential benefits of this approach make it an exciting area of research for cancer therapy.

*Correspondence to

Nikolaus Gibran,
Department of Pharmacology,
University in Dortmund,
Poststell,
Germany,
E-mail: gibran.nikolaus@pei.de

Citation: *Nikolaus G. Nanoparticle-Mediated Targeted Drug Delivery for Cancer Therapy: Recent Advances and Future Prospects AJPTI 2023;11(40):1-2.*